{
    "nct_id": "NCT05957042",
    "official_title": "Pilot Study to Evaluate if Contrast Enhanced Ultrasound (CEUS) Can Predict Treatment Response in Triple Negative Breast Cancer (TNBC) Patients Receiving Combined Chemotherapy and Immune Checkpoint Inhibitors (ICI).",
    "inclusion_criteria": "* Willingness and ability to sign and date the study-specific informed consent form.\n* Stated willingness to comply with all study procedures and attend all study visits to the best of his or her ability for the duration of the study.\n* Age greater than 18yo.\n* Stage I-III TNBC or stage IV TNBC with intact breast primary.\n* Planned combined ICI therapy as per SoC by treating oncologist.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Other clinical trials are not excluded but participation must be cleared with the other clinical trial PIs.\n* Patients not suitable to undergo contrast enhanced ultrasound (i.e., pregnant women, known allergy to eggs, or a past allergic reaction to sonographic contrast or its components, such as polyethylene glycol (PEG))",
    "miscellaneous_criteria": ""
}